Enliven Therapeutics's total assets for Q3 2025 were $490.88M, a decrease of -2.58% from the previous quarter. ELVN total liabilities were $14.75M for the fiscal quarter, a -4.29% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.